olanzalet od disp.tab 10mg/tab
teva gmbh, germany graf-arco-strasse 3,, 89079 ulm, - olanzapine - disp.tab (ΔΙΑΣΠΕΙΡΩΜΕΝΟ ΔΙΣΚΙΟ) - 10mg/tab - olanzapine 10mg - olanzapine
olanzalet od disp.tab 20mg/tab
teva gmbh, germany graf-arco-strasse 3,, 89079 ulm, - olanzapine - disp.tab (ΔΙΑΣΠΕΙΡΩΜΕΝΟ ΔΙΣΚΙΟ) - 20mg/tab - olanzapine 20mg - olanzapine
enteroporc coli ac
ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - Χοίροι - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:- clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6- clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins- clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - Καρκίνωμα, σκουός κύτταρο - Αντινεοπλασματικοί παράγοντες - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
geodon caps 20mg/cap
upjohn ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΤΑΙΡΕΙΑ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΕΥΘΥΝΗΣ Δ.Τ. upjohn hellas Ε.Π.Ε. Λ. Μεσογείων 253-255, 15451 n. Ψυχικό - ziprasidone hydrochloride monohydrate - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 20mg/cap - ziprasidone hydrochloride monohydrate 22,65mg - ziprasidone
geodon caps 40mg/cap
upjohn ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΤΑΙΡΕΙΑ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΕΥΘΥΝΗΣ Δ.Τ. upjohn hellas Ε.Π.Ε. Λ. Μεσογείων 253-255, 15451 n. Ψυχικό - ziprasidone hydrochloride monohydrate - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 40mg/cap - ziprasidone hydrochloride monohydrate 45,3mg - ziprasidone
geodon caps 60mg/cap
upjohn ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΤΑΙΡΕΙΑ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΕΥΘΥΝΗΣ Δ.Τ. upjohn hellas Ε.Π.Ε. Λ. Μεσογείων 253-255, 15451 n. Ψυχικό - ziprasidone hydrochloride monohydrate - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 60mg/cap - ziprasidone hydrochloride monohydrate 67,95mg - ziprasidone
geodon caps 80mg/cap
upjohn ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΤΑΙΡΕΙΑ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΕΥΘΥΝΗΣ Δ.Τ. upjohn hellas Ε.Π.Ε. Λ. Μεσογείων 253-255, 15451 n. Ψυχικό - ziprasidone hydrochloride monohydrate - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 80mg/cap - ziprasidone hydrochloride monohydrate 90,6mg - ziprasidone
nimbex 2mg/ml solution for injection or infusion
aspen pharma trading limited (0000009582) 3016 lake drive, citywest business campus, dublin 24, d24 x586 - cisatracurium besilate - solution for injection or infusion - 2mg/ml - cisatracurium besilate (8000001647) 2,68mg - cisatracurium
enteroporc coli
ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - Ανοσολογικά για τις αρουραίους - Χοίροι - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.